Bioxcel TherapeuticsBTAIQ
13F holders, Q2 2026 (June 30)At the end of Q2 2026, 47 institutions reported holding Bioxcel Therapeutics Inc. (BTAIQ) in their 13F filings, up 7 from Q1 2026. 10 opened new positions and 3 sold out. The largest holders were Millennium Management ($3.0M), Oaktree Capital Management ($1.9M) and Vanguard Capital Management LLC ($1.3M). 3 famous investors held it, including Howard Marks (0.1% of Oaktree Capital Management's portfolio), Israel Englander (0.0% of Millennium Management's portfolio) and Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Bioxcel Therapeutics Inc.
- CUSIP
- 09075P204
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 10 | $411K |
| Exits | 3 | $2.7M |
All 13F filers, Q1 2026 → Q2 2026: 2,820,702 shares bought and 2,085,932 shares sold, net +734,770 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 47 holders
| Millennium Management | 0.00% | Add +9.2% | 2,114,710 | $3.0M |
| Oaktree Capital Management | 0.05% | Add +472.3% | 1,380,248 | $1.9M |
| Vanguard Capital Management LLC | 0.00% | Add +343.5% | 919,545 | $1.3M |
| Oaktree Fund Advisors, LLC | 0.60% | Add +472.3% | 245,585 | $346K |
| Geode Capital Management, LLC | 0.00% | Add +5.3% | 242,251 | $342K |
| BlackRock, Inc. | 0.00% | Add +112.9% | 179,433 | $253K |
| UBS Group AG | 0.00% | Add +199.4% | 158,065 | $223K |
| Citadel Advisors | 0.00% | New | 149,220 | $210K |
| Vanguard Fiduciary Trust Co. | 0.00% | Add +61.3% | 136,937 | $193K |
| State Street Corp. | 0.00% | No change | 92,118 | $130K |
| FMR LLC | 0.00% | No change | 90,300 | $127K |
| &partners | 0.00% | Add +3.4% | 83,588 | $118K |
| Jones Financial Companies LLLP | 0.00% | Reduce -52.1% | 63,139 | $83K |
| Northern Trust Corp. | 0.00% | Add +55.1% | 56,318 | $79K |
| HighTower Advisors, LLC | 0.00% | No change | 41,000 | $58K |
| Quadrature Capital Ltd | 0.00% | New | 38,038 | $54K |
| Headlands Technologies LLC | 0.00% | New | 25,556 | $36K |
| StoneX Group Inc. | 0.00% | New | 20,684 | $29K |
| Beacon Pointe Advisors, LLC | 0.00% | Reduce -0.2% | 18,837 | $27K |
| Susquehanna International Group, LLP | 0.00% | New | 17,200 | $24K |
| Portfolio Strategies, Inc. | 0.00% | Add +38.2% | 16,831 | $24K |
| Virtu Financial LLC | 0.00% | New | 15,967 | $23K |
| Osaic Holdings, Inc. | 0.00% | No change | 16,214 | $23K |
| Two Sigma Securities, LLC | 0.00% | New | 10,796 | $15K |
| Diversify Advisory Services, LLC | 0.00% | New | 15,000 | $13K |
| Diversify Wealth Management, LLC | 0.00% | No change | 15,000 | $13K |
| Wells Fargo & Company | 0.00% | Add +0.4% | 4,337 | $6K |
| Citigroup Inc. | 0.00% | New | 2,998 | $4K |
| Morgan Stanley | 0.00% | Reduce -84.2% | 1,671 | $2K |
| Barclays PLC | 0.00% | New | 1,428 | $2K |
| NewEdge Advisors, LLC | 0.00% | No change | 1,331 | $2K |
| Vanguard Global Advisers, LLC | 0.00% | No change | 493 | $695 |
| Silver Grove Financial Group, Inc. | 0.00% | Reduce -0.9% | 331 | $468 |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -86.8% | 227 | $320 |
| Parkside Financial Bank & Trust | 0.00% | No change | 112 | $158 |
| Washington Trust Advisors, Inc. | 0.00% | Reduce -48.8% | 82 | $116 |
| EverSource Wealth Advisors, LLC | 0.00% | No change | 60 | $85 |
| JPMorgan Chase & Co. | 0.00% | No change | 45 | $63 |
| Farther Finance Advisors, LLC | 0.00% | No change | 25 | $35 |
| Northwestern Mutual Wealth Management Co. | 0.00% | No change | 21 | $30 |
| IFP Advisors, Inc | 0.00% | No change | 13 | $18 |
| SBI Securities Co., Ltd. | 0.00% | Reduce -7.1% | 13 | $18 |
| BNP Paribas Financial Markets | 0.00% | Reduce -79.7% | 12 | $17 |
| Zurcher Kantonalbank (Zurich Cantonalbank) | 0.00% | No change | 2 | $3 |
| US Bancorp \de | 0.00% | No change | 1 | $1 |
| Group One Trading LLC | 0.00% | No change | 1 | $1 |
| Triumph Capital Management | 0.00% | No change | 1 | $1 |
"% of holder's portfolio" is BTAIQ's weight in each manager's 13F, not the share of Bioxcel Therapeutics Inc. the manager owns.